Retatrutide typical research dosing
Across the available literature, Retatrutide is most commonly administered at 1000–12000 mcg per dose, 1 time(s) per day, via subcutaneous injection. Phase II studied doses of 1, 2, 4, 8, and 12 mg weekly with a titration scheme similar to other GLP-1 class agents. As retatrutide is still investigational, doses outside of clinical trials are not established. Dose values are in mcg for consistency with the database schema (1000–12000 mcg = 1–12 mg).
Retatrutide unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 5 mg Retatrutide vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 1000 mcg | 6500 mcg | 12000 mcg |
|---|---|---|---|---|
| 1 mL | 5000 mcg/mL | 20.0 units | 130.0 units | 240.0 units |
| 2 mL | 2500 mcg/mL | 40.0 units | 260.0 units | 480.0 units |
| 3 mL | 1667 mcg/mL | 60.0 units | 390.0 units | 720.0 units |
| 5 mL | 1000 mcg/mL | 100.0 units | 650.0 units | 1200.0 units |
Retatrutide cycle length
Most reported Retatrutide protocols run 48 weeks on, then 0 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Retatrutide half-life and timing
Retatrutide has a half-life of approximately 144 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.